Kymera Therapeutics (KYMR)

Kymera Therapeutics Stock Analysis & Ratings

KYMR Stock Chart & Stats

Day’s Range$17.05 - $18.02
52-Week Range$15.74 - $69.12
Previous Close$16.9
Average Volume (3M)520.56K
Market Cap$902.07M
P/E Ratio-7.0
Next EarningsAug 05, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score9
EPS (TTM)-2.48



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $15.74 and its highest was $69.12 in the past 12 months.
    What is Kymera Therapeutics’s market cap?
    Kymera Therapeutics’s market cap is $902.07M.
      What is Kymera Therapeutics’s price target?
      The average price target for Kymera Therapeutics is $60.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $85.00 ,the lowest forecast is $35.00. The average price target represents 245.47% Increase from the current price of $17.44.
        What do analysts say about Kymera Therapeutics?
        Kymera Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
          When is Kymera Therapeutics’s upcoming earnings report date?
          Kymera Therapeutics’s upcoming earnings report date is Aug 05, 2022 which is in 81 days.
            How were Kymera Therapeutics’s earnings last quarter?
            Kymera Therapeutics released its earnings results on May 03, 2022. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.042.
              Is Kymera Therapeutics overvalued?
              According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
                Does Kymera Therapeutics pay dividends?
                Kymera Therapeutics does not currently pay dividends.
                What is Kymera Therapeutics’s EPS estimate?
                Kymera Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Kymera Therapeutics have?
                Kymera Therapeutics has 51,720,000 shares outstanding.
                  What happened to Kymera Therapeutics’s price movement after its last earnings report?
                  Kymera Therapeutics reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -23.984%.
                    Which hedge fund is a major shareholder of Kymera Therapeutics?
                    Among the largest hedge funds holding Kymera Therapeutics’s share is Driehaus Capital Management LLC. It holds Kymera Therapeutics’s shares valued at 41M.


                      Kymera Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(245.47% Upside)
                      Strong Buy
                      The Kymera Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Kymera Therapeutics

                      Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis